Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?"

Shira Zelber-Sagi¹, Yochai Schonmann², Hanny Yeshua³, Itay Bentov⁴

Affiliations

¹ School of Public Health, University of Haifa, 3498838 Haifa, Israel; Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center, 6423906 Tel-Aviv, Israel. Electronic address: zelbersagi@bezeqint.net.
² Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Department of Quality Measurements and Research, Clalit Health Services, Tel Aviv, Israel.
³ Clalit Health Services, Tel-Aviv District, Israel; Department of Family Medicine, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
⁴ Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, United States.

PMID: 33509738
DOI: 10.1016/j.dld.2021.01.014

Comment

Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?"

Shira Zelber-Sagi et al. Dig Liver Dis. 2021 Mar.

. 2021 Mar;53(3):385-386.

doi: 10.1016/j.dld.2021.01.014. Epub 2021 Jan 25.

Authors

Shira Zelber-Sagi¹, Yochai Schonmann², Hanny Yeshua³, Itay Bentov⁴

Affiliations

¹ School of Public Health, University of Haifa, 3498838 Haifa, Israel; Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center, 6423906 Tel-Aviv, Israel. Electronic address: zelbersagi@bezeqint.net.
² Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Department of Quality Measurements and Research, Clalit Health Services, Tel Aviv, Israel.
³ Clalit Health Services, Tel-Aviv District, Israel; Department of Family Medicine, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
⁴ Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, WA, United States.

PMID: 33509738
DOI: 10.1016/j.dld.2021.01.014

No abstract available

Keywords: Cardiovascular; Fibrosis marker; NAFLD; Primary care; Primary prevention.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Comment on

Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population.
Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Schonmann Y, et al. Dig Liver Dis. 2021 Jan;53(1):79-85. doi: 10.1016/j.dld.2020.10.014. Epub 2020 Nov 2. Dig Liver Dis. 2021. PMID: 33144054
Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?
Angelico F, Baratta F, Pastori D, Ben MD. Angelico F, et al. Dig Liver Dis. 2021 Mar;53(3):383-384. doi: 10.1016/j.dld.2020.12.123. Epub 2021 Jan 20. Dig Liver Dis. 2021. PMID: 33483258 No abstract available.

Cited by

An international multidisciplinary consensus statement on MAFLD and the risk of CVD.
Zhou XD, Targher G, Byrne CD, Somers V, Kim SU, Chahal CAA, Wong VW, Cai J, Shapiro MD, Eslam M, Steg PG, Sung KC, Misra A, Li JJ, Brotons C, Huang Y, Papatheodoridis GV, Sun A, Yilmaz Y, Chan WK, Huang H, Méndez-Sánchez N, Alqahtani SA, Cortez-Pinto H, Lip GYH, de Knegt RJ, Ocama P, Romero-Gomez M, Fudim M, Sebastiani G, Son JW, Ryan JD, Ikonomidis I, Treeprasertsuk S, Pastori D, Lupsor-Platon M, Tilg H, Ghazinyan H, Boursier J, Hamaguchi M, Nguyen MH, Fan JG, Goh GB, Al Mahtab M, Hamid S, Perera N, George J, Zheng MH. Zhou XD, et al. Hepatol Int. 2023 Aug;17(4):773-791. doi: 10.1007/s12072-023-10543-8. Epub 2023 May 19. Hepatol Int. 2023. PMID: 37204656 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?"

Affiliations

Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?"

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical